ProQR Q3 revenue misses estimates, reports net loss

Reuters11-06

ProQR Q3 revenue misses estimates, reports net loss

Overview

ProQR Q3 revenue missed analyst expectations
Company reported a net loss of €11 mln for Q3 2025
ProQR received CTA authorization for Phase 1 trial of AX-0810

Outlook

ProQR expects initial safety data for AX-0810 by end of 2025
Target engagement data for AX-0810 expected in H1 2026

Result Drivers

CASH POSITION - Strong cash position provides runway into mid-2027, supporting pipeline and partnership activities

Key Details

Metric	Beat/Miss	Actual	Consensus Estimate
Q3 Revenue	Miss	EUR 2.88 mln	EUR 4.36 mln (7 Analysts)
Q3 EPS		-EUR 0.10
Q3 Net Income		-EUR 11.01 mln
Q3 Basic EPS		-EUR 0.10
Q3 Operating Income		-EUR 11.28 mln

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 9 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for ProQR Therapeutics NV is $8.50, about 72% above its November 5 closing price of $2.38

Press Release: ID:nGNE4ZCg56

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2581062243?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-06 20:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2581062243","market":"fut","top_or_hot":-1,"title":"ProQR Q3 revenue misses estimates, reports net loss","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ProQR Q3 revenue misses estimates, reports net loss</title></head><body><p><span>Overview</span></p><ul><li><p>ProQR Q3 revenue missed analyst expectations</p></li><li><p>Company reported a net loss of €11 mln for Q3 2025</p></li><li><p>ProQR received CTA authorization for Phase 1 trial of AX-0810</p></li></ul><p><span>Outlook</span></p><ul><li><p>ProQR expects initial safety data for AX-0810 by end of 2025</p></li><li><p>Target engagement data for AX-0810 expected in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CASH POSITION - Strong cash position provides runway into mid-2027, supporting pipeline and partnership activities</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>EUR 2.88 mln</p></td><td><p>EUR 4.36 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-EUR 0.10</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-EUR 11.01 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-EUR 0.10</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-EUR 11.28 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV is $8.50, about 72% above its November 5 closing price of $2.38</p></li></ul><p>Press Release: <span>ID:nGNE4ZCg56</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ProQR Q3 revenue misses estimates, reports net loss</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProQR Q3 revenue misses estimates, reports net loss\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-11-06 20:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\"><head><title>ProQR Q3 revenue misses estimates, reports net loss</title></head><body><p><span>Overview</span></p><ul><li><p>ProQR Q3 revenue missed analyst expectations</p></li><li><p>Company reported a net loss of €11 mln for Q3 2025</p></li><li><p>ProQR received CTA authorization for Phase 1 trial of AX-0810</p></li></ul><p><span>Outlook</span></p><ul><li><p>ProQR expects initial safety data for AX-0810 by end of 2025</p></li><li><p>Target engagement data for AX-0810 expected in H1 2026</p></li></ul><p><span>Result Drivers</span></p><ul><li><p>CASH POSITION - Strong cash position provides runway into mid-2027, supporting pipeline and partnership activities</p></li></ul><p><span>Key Details</span></p><table><tbody><tr><td><p><span>Metric</span></p></td><td><p><span>Beat/Miss</span></p></td><td><p><span>Actual</span></p></td><td><p><span>Consensus Estimate</span></p></td></tr><tr><td><p>Q3 Revenue</p></td><td><p>Miss</p></td><td><p>EUR 2.88 mln</p></td><td><p>EUR 4.36 mln (7 Analysts)</p></td></tr><tr><td><p>Q3 EPS</p></td><td></td><td><p>-EUR 0.10</p></td><td></td></tr><tr><td><p>Q3 Net Income</p></td><td></td><td><p>-EUR 11.01 mln</p></td><td></td></tr><tr><td><p>Q3 Basic EPS</p></td><td></td><td><p>-EUR 0.10</p></td><td></td></tr><tr><td><p>Q3 Operating Income</p></td><td></td><td><p>-EUR 11.28 mln</p></td><td></td></tr></tbody></table><p><span>Analyst Coverage</span></p><ul><li><p>The current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"</p></li><li><p>The average consensus recommendation for the biotechnology &amp; medical research peer group is \"buy\"</p></li><li><p>Wall Street's median 12-month price target for ProQR <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> NV is $8.50, about 72% above its November 5 closing price of $2.38</p></li></ul><p>Press Release: <span>ID:nGNE4ZCg56</span></p><p>For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.</p><p>(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRQR","symbol_name":"ProQR Therapeutics N.V.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251106:nL1N3WI0JZ:1","article_id":"2581062243","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2581062243","pubTimestamp":1762430878,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ProQR Q3 revenue misses estimates, reports net lossOverviewProQR Q3 revenue missed analyst expectationsCompany reported a net loss of 11 mln for Q3 2025ProQR received CTA authorization for Phase 1 tri","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRQR":"ProQR Therapeutics N.V.","BK4139":"生物科技"},"translate_title":"ProQR第三季度收入未达预期，报告净亏损","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRQR":0.9},"content_text":"ProQR Q3 revenue misses estimates, reports net lossOverviewProQR Q3 revenue missed analyst expectationsCompany reported a net loss of €11 mln for Q3 2025ProQR received CTA authorization for Phase 1 trial of AX-0810OutlookProQR expects initial safety data for AX-0810 by end of 2025Target engagement data for AX-0810 expected in H1 2026Result DriversCASH POSITION - Strong cash position provides runway into mid-2027, supporting pipeline and partnership activitiesKey DetailsMetricBeat/MissActualConsensus EstimateQ3 RevenueMissEUR 2.88 mlnEUR 4.36 mln (7 Analysts)Q3 EPS-EUR 0.10Q3 Net Income-EUR 11.01 mlnQ3 Basic EPS-EUR 0.10Q3 Operating Income-EUR 11.28 mlnAnalyst CoverageThe current average analyst rating on the shares is \"buy\" and the breakdown of recommendations is 9 \"strong buy\" or \"buy\", no \"hold\" and no \"sell\" or \"strong sell\"The average consensus recommendation for the biotechnology & medical research peer group is \"buy\"Wall Street's median 12-month price target for ProQR Therapeutics NV is $8.50, about 72% above its November 5 closing price of $2.38Press Release: ID:nGNE4ZCg56For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2581062243","isCrawlerRequest":true}